Meeting of the National Advisory Council for Healthcare Research and Quality, 14730-14731 [2017-05588]
Download as PDF
<![CDATA[
14730
Federal Register / Vol. 82, No. 54 / Wednesday, March 22, 2017 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
October 12, 2016. No comments were
received.
DATES: Submit comments on or before
April 21, 2017.
ADDRESSES: Submit comments regarding
this burden estimate or any other aspect
of this collection of information,
including suggestions for reducing this
burden to: Office of Information and
Regulatory Affairs of OMB, Attention:
Desk Officer for GSA, Room 10236,
NEOB, Washington, DC 20503.
Additionally submit a copy to GSA by
any of the following methods:
• Regulations.gov: https://
www.regulations.gov. Submit comments
via the Federal eRulemaking portal by
searching the OMB control number
9000–0138. Select the link ‘‘Comment
Now’’ that corresponds with
‘‘Information Collection 9000–0138,
Contract Financing’’. Follow the
instructions provided on the screen.
Please include your name, company
name (if any), and ‘‘Information
Collection 9000–0138, Contract
Financing’’ on your attached document.
• Mail: General Services
Administration, Regulatory Secretariat
Division (MVCB), 1800 F Street NW.,
Washington, DC 20405. ATTN: Ms.
Sosa/IC 9000–0138.
Instructions: Please submit comments
only and cite Information Collection
9000–0138, in all correspondence
related to this collection. Comments
received generally will be posted
without change to https://
www.regulations.gov, including any
personal and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check www.regulations.gov,
approximately two to three days after
submission to verify posting (except
allow 30 days for posting of comments
submitted by mail).
FOR FURTHER INFORMATION CONTACT: Ms.
Camara Francis, Procurement Analyst,
Acquisition Policy Division, at 202–
501–1448 or email camara.francis@
gsa.gov.
SUPPLEMENTARY INFORMATION:
A. Purpose
The Federal Acquisition Streamlining
Act (FASA) of 1994, Public Law 103–
355, provided authorities that
streamlined the acquisition process and
minimize burdensome Governmentunique requirements. Sections 2001 and
2051 of FASA substantially changed the
statutory authorities for Government
financing of contracts. Sections 2001(f)
and 2051(e) provide specific authority
for Government financing of purchases
of commercial items; here, contract
financing is permitted with certain
VerDate Sep<11>2014
18:14 Mar 21, 2017
Jkt 241001
limitations. Likewise, sections 2001(b)
and 2051(b) substantially revised the
authority for Government financing of
purchases of non-commercial items, by
permitting contract financing on the
basis of certain classes of measures of
performance.
To implement these changes, DOD,
NASA, and GSA amended the FAR by
revising Subparts 32.0, 32.1, and 32.5;
by adding new Subparts 32.2 and 32.10;
and by adding new clauses to 52.232.
The coverage enables the Government
to provide financing to assist in the
performance of contracts for commercial
items and provide financing for noncommercial items based on contractor
performance.
B. Annual Reporting Burden
Public reporting burden for this
collection of information is estimated to
average 2 hours per request for
commercial financing and 2 hours per
request for performance-based
financing, including time for reviewing
instructions, searching existing data
sources, gathering and maintaining the
data needed, and completing and
reviewing the collection of information.
The annual reporting burden for
commercial financing is estimated as
follows:
Respondents: 1,000.
Responses per Respondent: 5.
Total Responses: 5,000.
Hours per Response: 2.
Total Burden Hours: 10,000.
The annual reporting burden for
performance-based financing is
estimated as follows:
Respondents: 500.
Responses per Respondent: 12.
Total Responses: 6,000.
Hours per Response: 2.
Total Burden Hours: 12,000.
C. Public Comments
Public comments are particularly
invited on: Whether this collection of
information is necessary for the proper
performance of functions of the FAR,
and whether it will have practical
utility; whether our estimate of the
public burden of this collection of
information is accurate, and based on
valid assumptions and methodology;
ways to enhance the quality, utility, and
clarity of the information to be
collected; and ways in which we can
minimize the burden of the collection of
information on those who are to
respond, through the use of appropriate
technological collection techniques or
other forms of information technology.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Regulatory Secretariat Division (MVCB),
1800 F Street NW., Washington, DC
20405, telephone 202–501–4755. Please
cite OMB Control No. 9000–0138,
Contract Financing, in all
correspondence.
Dated: March 16, 2017.
Lorin S. Curit,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2017–05570 Filed 3–21–17; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Meeting of the National Advisory
Council for Healthcare Research and
Quality
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Notice of public meeting
cancellation.
AGENCY:
In accordance with section
10(a) of the Federal Advisory Committee
Act, 5 U.S.C. App. 2, this notice
announces the cancellation of a meeting
of the National Advisory Council for
Healthcare Research and Quality.
DATES: The meeting would have been
held on Friday, March 24, 2017, from
8:30 a.m. to 2:45 p.m.
ADDRESSES: The meeting would have
been held at the Hubert H. Humphrey
Building, Room 800, 200 Independence
Avenue SW., Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
Jaime Zimmerman, Designated
Management Official, at the Agency for
Healthcare Research and Quality, 5600
Fishers Lane, Mail Stop 06E37A,
Rockville, Maryland, 20857, (301) 427–
1456. For press-related information,
please contact Alison Hunt at (301) 427–
1244 or Alison.Hunt@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Purpose
The National Advisory Council for
Healthcare Research and Quality is
authorized by Section 941 of the Public
Health Service Act, 42 U.S.C. 299c. In
accordance with its statutory mandate,
the Council is to advise the Secretary of
the Department of Health and Human
Services and the Director of AHRQ on
matters related to AHRQ’s conduct of its
mission including providing guidance
on (A) priorities for health care research,
(B) the field of health care research
E:\FR\FM\22MRN1.SGM
22MRN1
Federal Register / Vol. 82, No. 54 / Wednesday, March 22, 2017 / Notices
including training needs and
information dissemination on health
care quality and (C) the role of the
Agency in light of private sector activity
and opportunities for public private
partnerships. The Council is composed
of members of the public, appointed by
the Secretary, and Federal ex-officio
members specified in the authorizing
legislation. The Council did not have a
quorum for the meeting scheduled for
March 24th. Therefore, AHRQ is
cancelling the meeting. The next
meeting of the NAC is planned for July
26th.
Sharon B. Arnold,
Acting Director.
[FR Doc. 2017–05588 Filed 3–21–17; 8:45 am]
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[60-Day–17–17XR; Docket No. CDC–2017–
0027]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on the donor registration form
in support of the project titled
‘‘Acquisition of Freshly Drawn Whole
Blood/Blood Products for Reference
Diagnostic and Research Use.’’
DATES: Written comments must be
received on or before May 22, 2017.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2017–
0027 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:14 Mar 21, 2017
Jkt 241001
to Regulations.gov, including any
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment should be
submitted through the Federal eRulemaking
portal (Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT:
To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
14731
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Acquisition of Freshly-Drawn Whole
Blood/Blood Products for Reference
Diagnostic and Research Use—Existing
Information Collection in Use Without
an OMB Control Number—National
Center for Emerging and Zoonotic
Infectious Diseases (NCEZID), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The CDC seeks a three-year OMB
approval to collect information in
support of fresh blood/blood products
for laboratory programs.
The CDC regularly requires freshly
drawn whole blood, serum, plasma,
mononuclear white cell and platelet
concentrates for research purposes, for
reagents, and as ‘‘normal’’ control
materials. To enhance the safety of CDC
personnel handling these materials, the
blood/blood products, or the donors
thereof, must be screened for evidence
of possible infections by specific testing.
At the same time, donor confidentiality
must be assured and adequate
counseling must be available, in case
any specimens or donors test positive
for certain transmissible infections.
The donor registration form
referenced by this request is a brief, 11question form that establishes the
availability of volunteer donors to
participate in the donor program to fill
this need for fresh blood/blood products
for CDC. The registration form captures
donors’ availability to donate, interest in
various types of donations, smoking
history, exercise background, alcohol
consumption, measles vaccination
history, cholesterol test history, and
medications background.
Donors required to maintain the CDC
donor pool are recruited by contract
program managers often by referral of
current donors, directed outreach for
new donors by email, occasional posting
of notices in areas frequented by CDC
personnel, or at local universities for
possible student populations.
All donor information is collected and
protected by medical professionals with
donor/patient confidentiality protected.
Information from this form is only used
to determine donor eligibility for blood
product requests to be used by CDC
laboratory programs. Approximately 25
volunteer donors are enrolled annually.
E:\FR\FM\22MRN1.SGM
22MRN1
]]>Agencies
[Federal Register Volume 82, Number 54 (Wednesday, March 22, 2017)]
[Notices]
[Pages 14730-14731]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05588]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Meeting of the National Advisory Council for Healthcare Research
and Quality
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Notice of public meeting cancellation.
-----------------------------------------------------------------------
SUMMARY: In accordance with section 10(a) of the Federal Advisory
Committee Act, 5 U.S.C. App. 2, this notice announces the cancellation
of a meeting of the National Advisory Council for Healthcare Research
and Quality.
DATES: The meeting would have been held on Friday, March 24, 2017, from
8:30 a.m. to 2:45 p.m.
ADDRESSES: The meeting would have been held at the Hubert H. Humphrey
Building, Room 800, 200 Independence Avenue SW., Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT: Jaime Zimmerman, Designated Management
Official, at the Agency for Healthcare Research and Quality, 5600
Fishers Lane, Mail Stop 06E37A, Rockville, Maryland, 20857, (301) 427-
1456. For press-related information, please contact Alison Hunt at
(301) 427-1244 or Alison.Hunt@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Purpose
The National Advisory Council for Healthcare Research and Quality
is authorized by Section 941 of the Public Health Service Act, 42
U.S.C. 299c. In accordance with its statutory mandate, the Council is
to advise the Secretary of the Department of Health and Human Services
and the Director of AHRQ on matters related to AHRQ's conduct of its
mission including providing guidance on (A) priorities for health care
research, (B) the field of health care research
[[Page 14731]]
including training needs and information dissemination on health care
quality and (C) the role of the Agency in light of private sector
activity and opportunities for public private partnerships. The Council
is composed of members of the public, appointed by the Secretary, and
Federal ex-officio members specified in the authorizing legislation.
The Council did not have a quorum for the meeting scheduled for March
24th. Therefore, AHRQ is cancelling the meeting. The next meeting of
the NAC is planned for July 26th.
Sharon B. Arnold,
Acting Director.
[FR Doc. 2017-05588 Filed 3-21-17; 8:45 am]
BILLING CODE 4160-90-P
